From GlobeNewswire: 2025-05-18 07:28:00

Applied Therapeutics presented full 12-month clinical results and new topline data from the INSPIRE Phase 2/3 trial of govorestat for the treatment of CMT-SORD. The trial showed improvements in outcomes, reduction in sorbitol, and slowing of disease progression observed via MRI at 24 months. Govorestat treatment demonstrated a significant reduction in sorbitol in the sciatic nerve of CMT-SORD-Null rats. The company plans to submit a New Drug Application for govorestat in 2025. The treatment remains generally safe and well-tolerated. The INSPIRE trial is now in the open-label extension phase with 90% of patients continuing govorestat treatment.



Read more at GlobeNewswire: Applied Therapeutics Presents Full 12-Month Clinical